Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras.
Heterologous expression systems have increased the feasibility of developing selective ligands to target nicotinic acetylcholine receptor (nAChR) subtypes. However, the alpha6 subunit, a component in nAChRs that mediates some of the reinforcing effects of nicotine, is not easily expressed in systems such as the Xenopus oocyte. Certain aspects of alpha6-containing receptor pharmacology have been studied by using chimeric subunits containing the alpha6 ligand-binding domain. However, these chimeras would not be sensitive to an alpha6-selective channel blocker; therefore we developed an alpha6 chimera (alpha4/6) that has the transmembrane and intracellular domains of alpha6 and the extracellular domain of alpha4. We examined the pharmacological properties of alpha4/6-containing receptors and other important nAChR subtypes, including alpha7, alpha4beta2, alpha4beta4, alpha3beta4, alpha3beta2, and alpha3beta2beta3, as well as receptors containing alpha6/3 and alpha6/4 chimeras. Our data show that the absence or presence of the beta4 subunit is an important factor for sensitivity to the ganglionic blocker mecamylamine, and that dihydro-beta-erythroidine is most effective on subtypes containing the alpha4 subunit extracellular domain. Receptors containing the alpha6/4 subunit are sensitive to alpha-conotoxin PIA, while receptors containing the reciprocal alpha4/6 chimera are insensitive. In experiments with novel antagonists of nicotine-evoked dopamine release, the alpha4/6 chimera indicated that structural rigidity was a key element of compounds that could result in selectivity for noncompetitive inhibition of alpha6-containing receptors. Our data extend the information available on prototypical nAChR antagonists, and establish the alpha4/6 chimera as a useful new tool for screening drugs as selective nAChR antagonists.
Papke
Roger L
RL
Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, P.O. Box 100267, JHMHSC, 1600 SW Archer Road, Gainesville, FL 32610-0267, USA. rlpapke@ufl.edu
Dwoskin
Linda P
LP
Crooks
Peter A
PA
Zheng
Guangrong
G
Zhang
Zhenfa
Z
McIntosh
J Michael
JM
Stokes
Clare
C
D000109:Acetylcholine / Q000494:pharmacology; D000595:Amino Acid Sequence; D000818:Animals; D003001:Cloning, Molecular; D003627:Data Interpretation, Statistical; D004079:Dihydro-beta-Erythroidine / Q000494:pharmacology; D004594:Electrophysiology; D005260:Female; D008464:Mecamylamine / Q000494:pharmacology; D008968:Molecular Conformation; D008969:Molecular Sequence Data; D050506:Mutant Chimeric Proteins / Q000235:genetics*; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D009865:Oocytes / Q000378:metabolism; D018408:Patch-Clamp Techniques; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology; D012313:RNA / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D011978:Receptors, Nicotinic / Q000096:biosynthesis / Q000187:drug effects* / Q000235:genetics*; D013329:Structure-Activity Relationship; D014982:Xenopus laevis
D050506:Mutant Chimeric Proteins; D018733:Nicotinic Antagonists; D000644:Quaternary Ammonium Compounds; D011978:Receptors, Nicotinic; C104518:nicotinic receptor alpha6; D004079:Dihydro-beta-Erythroidine; D012313:RNA; D008464:Mecamylamine; D000109:Acetylcholine